AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.

Enrollment completed for BLP25 liposomal vaccine.

Drug Week

| December 27, 2002 | COPYRIGHT 2002 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan.  All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)Copyright

2002 DEC 27 - (NewsRx.com & NewsRx.net) -- Biomira, Inc., (BIOM, BRA) announced that the company has completed enrollment of the planned 166 patients in its phase IIb clinical trial with BLP25 Liposomal vaccine.

There are now 168 patients enrolled into the trial. The controlled, randomized study involves patients with advanced non-small cell lung cancer (NSCLC) and enrollment was conducted at 13 sites in Canada and four in the United Kingdom. The trial began in August 2000. Final recruitment in the trial has been extended to allow a few previously identified patients the opportunity to be included in the trial. Enrollment for these identified patients is expected to close later this month.

Since the enrollment of patients in the trial began, two Data Safety Monitoring Board (DSMB) reviews have taken place, of the first 50 patients and the first 100 patients who had passed the primary treatment period. The DSMB, comprising experts in oncology who are not affiliated with the trial, recommended that the study continue as planned.

"This is another milestone for our company as we advance our product candidates toward potential commercialization," said Alex McPherson, MD, PhD, president, and CEO. "We believe this accomplishment continues to position Biomira as a leader in bringing forth novel immunotherapeutic approaches to the treatment of cancer through the development of cancer vaccines."

All patients in this trial were required to be stable or responding following completion of their first line standard chemotherapy for treatment of Stage IIIb and IV NSCLC. Patients were then randomized to BLP25 Liposomal vaccine, plus best supportive care or to best supportive care alone. Best supportive care can include local radiotherapy and second line chemotherapy, according to current standard clinical practice.

Objectives of this trial are to measure the safety and potential survival benefit of BLP25 Liposomal vaccine in patients with NSCLC. Secondary endpoints of the trial are quality of life and immune response. All cumulative efficacy data remain fully blinded to until the final analysis. The analysis is event driven and the timing is dependent on when clinical events occur. The required event level is expected by mid-2003 with the final analysis commencing thereafter.

BLP25 Liposomal vaccine is a synthetic MUC1 peptide vaccine. The BLP25 Liposomal vaccine incorporates a 25-amino acid sequence of the MUC1 ...

Related articles from newspapers, magazines, journals, and more
Enrollment completed for BLP25 liposomal vaccine.
Newspaper article from: Biotech Week December 25, 2002 700+ words
...IIIb and IV NSCLC. Patients...to BLP25 Liposomal vaccine, plus best...and Stage IV NSCLC. In this...of BLP25 Liposomal vaccine was increased...and Stage IV NSCLC. Besides the BLP25 Liposomal vaccine phase IIb...
Biomira Completes Enrolment of BLP25 Liposomal Vaccine Phase IIB Study in...
Press release article from: PR Newswire November 13, 2002 700+ words
...IIIb and IV NSCLC. Patients...to BLP25 Liposomal vaccine, plus best...and Stage IV NSCLC. In this...of BLP25 Liposomal vaccine was increased...and Stage IV NSCLC. Besides the BLP25 Liposomal vaccine Phase IIb...
Biomira completes enrolment of BLP25 liposomal vaccine Phase IIB study in...
News wire article from: Asia Africa Intelligence Wire November 13, 2002 700+ words
...clinical trial with BLP25 Liposomal vaccine. There are now 168...of Stage IIIb and IV NSCLC. Patients were then randomised to BLP25 Liposomal vaccine, plus best supportive...survival benefit of BLP25 Liposomal vaccine in patients with NSCLC...
Biomira and Merck KGaA Announce Phase IIb BLP25 Liposomal Vaccine Trial in...
Press release article from: PR Newswire April 2, 2004 700+ words
...from a randomized, open-label Phase IIb trial of BLP25 liposomal vaccine (L BLP25) in patients with Stage IIIb and IV non- small...the Phase IIb trial for men and women with Stage IIIb and IV NSCLC, in 2002 Biomira also completed enrolment in a second pilot...
Biomira and Merck KGaA Announce Phase IIb BLP25 Liposomal Vaccine Trial - Final.
News wire article from: The America's Intelligence Wire April 2, 2004 700+ words
...of clinical trial results of BLP25 liposomal vaccine is preliminary and based upon data...Phase IIb clinical trial of BLP25 liposomal vaccine. I would like to particularly welcome...the patients who received the BLP25 liposomal vaccine plus best standard of care versus...
ASCO accepts BLP25 liposomal vaccine phase IIB trial results for presentation.
Newspaper article from: Respiratory Therapeutics Week April 19, 2004 700+ words
...com & NewsRx.net) -- Biomira, Inc., (BIOM, BRA) announced that data from the company's phase IIb BLP25 Liposomal vaccine (L-BLP25) trial in non-small cell lung cancer has been accepted as the subject of a poster presentation at the 2004...
Biomira Outlines Milestones For 2004; BLP25 Liposomal Vaccine Phase IIb Results...
Press release article from: PR Newswire December 19, 2003 700+ words
...for its product pipeline in 2004. One of the important milestone for 2004 is expected to be the results from the BLP 25 Liposomal vaccine (L-BLP25) Phase IIb study of 171 patients with non-small cell lung cancer. The final analysis is expected toward...
Positive results reported from phase IIb BLP25 liposomal vaccine trial.
Newspaper article from: Biotech Business Week April 26, 2004 700+ words
...Merck KGaA of Darmstadt, Germany, said preliminary results from a randomized, open-label phase IIb trial of BLP25 liposomal vaccine (L BLP25) in patients with Stage IIIb and IV non-small cell lung cancer (NSCLC) indicate that the median survival...
Biomira and Merck KGaA announce Phase IIb BLP25 Liposomal vaccine trial in...
News wire article from: Asia Africa Intelligence Wire April 2, 2004 700+ words
...Release) Biomira Inc and Merck KGaA said preliminary results from a randomised, open-label Phase IIb trial of BLP25 liposomal vaccine (L BLP25) in patients with Stage IIIb and IV non-small cell lung cancer (NSCLC) indicate that the median survival...
American Society of Clinical Oncology (ASCO) Accepts Biomira's BLP25 Liposomal...
Press release article from: PR Newswire March 25, 2004 700+ words
Biomira Inc. (TSX:BRA) announced today that data from the Company's Phase IIb BLP25 Liposomal vaccine (L-BLP25) trial in non-small cell lung cancer has been accepted as the subject of a poster presentation at the 2004 Annual...
For more facts and information, see all results

Source: HighBeam Research, Enrollment completed for BLP25 liposomal vaccine.

©2009 Gale, a part of Cengage Learning. All rights reserved.
About us | FAQs | Contact us | Privacy policy | Terms and conditions
Other Gale sites: Encyclopedia.com | HighBeam Research | Acquire Content | Books & Authors | Goliath | MovieRetriever | Smart QandA